0.425 -0.007 (-1.67%) | 05-16 11:28 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.62 ![]() |
1-year : | 0.73 |
Resists | First : | 0.53 ![]() |
Second : | 0.63 |
Pivot price | 0.48 ![]() |
|||
Supports | First : | 0.37 ![]() |
Second : | 0.31 ![]() |
MAs | MA(5) : | 0.47 ![]() |
MA(20) : | 0.47 ![]() |
MA(100) : | 0.44 ![]() |
MA(250) : | 0.49 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 12.9 ![]() |
D(3) : | 26.6 ![]() |
RSI | RSI(14): 44.2 ![]() |
|||
52-week | High : | 1.29 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BTCY ] has closed above bottom band by 12.4%. Bollinger Bands are 28.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.43 - 0.44 | 0.44 - 0.44 |
Low: | 0.41 - 0.41 | 0.41 - 0.41 |
Close: | 0.41 - 0.41 | 0.41 - 0.42 |
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Thu, 15 May 2025
Biotricity (OTCMKTS:BTCY) Stock Price Down 5.2% – Here’s What Happened - Defense World
Tue, 08 Apr 2025
Biotricity Recognized by Financial Times as One of 2025’s - GlobeNewswire
Tue, 08 Apr 2025
Healthcare Tech Leader Biotricity's Massive 256% Growth Lands Coveted FT Recognition - Stock Titan
Wed, 12 Mar 2025
Shares Of This Micro Cap Rally On IP Expansion News - The Globe and Mail
Wed, 19 Feb 2025
BIOTRICITY INC. SEC 10-Q Report - TradingView
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
OTC
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 22 (M) |
Shares Float | 15 (M) |
Held by Insiders | 46.5 (%) |
Held by Institutions | 4.1 (%) |
Shares Short | 460 (K) |
Shares Short P.Month | 503 (K) |
EPS | -1.75 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.38 |
Profit Margin | -117.5 % |
Operating Margin | -34.9 % |
Return on Assets (ttm) | -82.5 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 6 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.54 |
EBITDA (p.s.) | -0.34 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -6 (M) |
Levered Free Cash Flow | -4 (M) |
PE Ratio | -0.25 |
PEG Ratio | 0 |
Price to Book value | -0.31 |
Price to Sales | 0.77 |
Price to Cash Flow | -1.51 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |